This open-label, randomized, multicenter trial aims to assess the efficacy and safety of BAY 2927088 as a first-line therapy in patients with locally advanced or metastatic NSCLC with HER2-activating mutations (69). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.